Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Axogen Inc (AXGN)

Axogen Inc (AXGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,510,034
  • Shares Outstanding, K 46,122
  • Annual Sales, $ 187,340 K
  • Annual Income, $ -9,960 K
  • EBIT $ 4 M
  • EBITDA $ 13 M
  • 60-Month Beta 1.06
  • Price/Sales 7.87
  • Price/Cash Flow N/A
  • Price/Book 12.21

Options Overview Details

View History
  • Implied Volatility 56.76% (-5.94%)
  • Historical Volatility 60.26%
  • IV Percentile 2%
  • IV Rank 5.21%
  • IV High 134.13% on 11/21/25
  • IV Low 52.50% on 12/10/25
  • Expected Move (DTE 24) 3.61 (11.33%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 21
  • Volume Avg (30-Day) 187
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 1,847
  • Open Int (30-Day) 4,926
  • Expected Range 28.27 to 35.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.01
  • Number of Estimates 3
  • High Estimate 0.00
  • Low Estimate -0.02
  • Prior Year 0.01
  • Growth Rate Est. (year over year) -200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.92 +18.95%
on 11/24/25
34.24 -6.48%
on 12/04/25
+5.15 (+19.17%)
since 11/21/25
3-Month
15.27 +109.69%
on 10/14/25
34.24 -6.48%
on 12/04/25
+14.72 (+85.09%)
since 09/23/25
52-Week
9.22 +247.48%
on 06/18/25
34.24 -6.48%
on 12/04/25
+14.83 (+86.27%)
since 12/23/24

Most Recent Stories

More News
Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference

ALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral...

AXGN : 32.25 (-1.50%)
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral...

AXGN : 32.25 (-1.50%)
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences

ALACHUA, Fla. and TAMPA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral...

AXGN : 32.25 (-1.50%)
AxoGen: Q3 Earnings Snapshot

AxoGen: Q3 Earnings Snapshot

AXGN : 32.25 (-1.50%)
Axogen, Inc. Reports Third Quarter 2025 Financial Results

ALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral...

AXGN : 32.25 (-1.50%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact...

AXGN : 32.25 (-1.50%)
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025

ALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral...

AXGN : 32.25 (-1.50%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact...

AXGN : 32.25 (-1.50%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact...

AXGN : 32.25 (-1.50%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN

NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Axogen, Inc. ("Axogen" or the "Company") (NASDAQ: AXGN). Such investors are advised to contact...

AXGN : 32.25 (-1.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

AxoGen, Inc. engages in developing and marketing surgical solutions for peripheral nerves. The company's portfolio of products includes Avance Nerve Graft(R), AxoGuard Nerve Connector(R), AxoGuard Nerve Protector(R), Avive Soft Tissue Membrane(R), AcroVal Neurosensory & Motor Testing System(R) and AxoTouch...

See More

Key Turning Points

3rd Resistance Point 34.80
2nd Resistance Point 33.97
1st Resistance Point 33.36
Last Price 32.25
1st Support Level 31.91
2nd Support Level 31.08
3rd Support Level 30.47

See More

52-Week High 34.24
Last Price 32.25
Fibonacci 61.8% 24.68
Fibonacci 50% 21.73
Fibonacci 38.2% 18.77
52-Week Low 9.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar